Wedbush Maintains Outperform on Cullinan Therapeutics, Raises Price Target to $42

Benzinga · 1d ago
Wedbush analyst Robert Driscoll maintains Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and raises the price target from $39 to $42.